These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38537558)

  • 41. Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux.
    Roman S; Keefer L; Imam H; Korrapati P; Mogni B; Eident K; Friesen L; Kahrilas PJ; Martinovich Z; Pandolfino JE
    Neurogastroenterol Motil; 2015 Nov; 27(11):1667-74. PubMed ID: 26337396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
    Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
    Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impedance-pH monitoring on medications does not reliably confirm the presence of gastroesophageal reflux disease in patients referred for antireflux surgery.
    Ward MA; Dunst CM; Teitelbaum EN; Halpin VJ; Reavis KM; Swanström LL; DeMeester SR
    Surg Endosc; 2018 Feb; 32(2):889-894. PubMed ID: 28779252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of Proton Pump Inhibitor Therapy for Laryngopharyngeal Reflux on Posttreatment Symptoms and Hypopharyngeal pH.
    Waxman J; Yalamanchali S; Valle ES; Pott T; Friedman M
    Otolaryngol Head Neck Surg; 2014 Jun; 150(6):1010-7. PubMed ID: 24647643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
    Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
    Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy.
    Blonski W; Vela MF; Castell DO
    J Clin Gastroenterol; 2009 Oct; 43(9):816-20. PubMed ID: 19398927
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation between oropharyngeal pH-monitoring and esophageal pH-impedance monitoring in patients with suspected GERD-related extra-esophageal symptoms.
    Mazzoleni G; Vailati C; Lisma DG; Testoni PA; Passaretti S
    Neurogastroenterol Motil; 2014 Nov; 26(11):1557-64. PubMed ID: 25208949
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical utility of salivary pepsin measurement in patients with proton pump inhibitor-refractory gastroesophageal reflux disease symptoms: a prospective comparative study.
    Matsumura T; Arai M; Suzuki T; Hoppo T; Seki Y; Kasamatsu S; Ishigami H; Ishikawa K; Okimoto K; Akizue N; Maruoka D; Nakagawa T; Odaka T; Okamoto Y; Kato N
    Esophagus; 2020 Jul; 17(3):339-347. PubMed ID: 31982992
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Laparoscopic magnetic sphincter augmentation versus double-dose proton pump inhibitors for management of moderate-to-severe regurgitation in GERD: a randomized controlled trial.
    Bell R; Lipham J; Louie B; Williams V; Luketich J; Hill M; Richards W; Dunst C; Lister D; McDowell-Jacobs L; Reardon P; Woods K; Gould J; Buckley FP; Kothari S; Khaitan L; Smith CD; Park A; Smith C; Jacobsen G; Abbas G; Katz P
    Gastrointest Endosc; 2019 Jan; 89(1):14-22.e1. PubMed ID: 30031018
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Correlation analysis between Dx-pH monitoring and proton pump inhibitor test in the diagnosis of laryngopharyngeal reflux disease].
    Chen ZL; Wu HW; Mei XW; Yin WH; Xu SY; Liu SQ; Chen YC; Wang G; Zhang CJ; Ding XL; Wu JN
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Jan; 55(1):34-39. PubMed ID: 31954386
    [No Abstract]   [Full Text] [Related]  

  • 51. Diagnosing Laryngopharyngeal Reflux: A Comparison between 24-hour pH-Impedance Testing and Pharyngeal Probe (Restech) Testing, with Introduction of the Sataloff Score.
    Vance D; Park J; Alnouri G; Turner RR; Daggumati S; Ferster APO; Ahmad A; Lyons K; Ross J; Russell K; Wu W; Sataloff RT
    J Voice; 2023 Sep; 37(5):737-747. PubMed ID: 34092465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
    Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
    Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased proximal reflux in a hypersensitive esophagus might explain symptoms resistant to proton pump inhibitors in patients with gastroesophageal reflux disease.
    Rohof WO; Bennink RJ; de Jonge H; Boeckxstaens GE
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1647-55. PubMed ID: 24184737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Signal detection theory approach to gastroesophageal reflux disease: a new method for symptom analysis of impedance-pH data.
    Giral A; Kurt R; Yeğin EG; Yeğin K
    Dis Esophagus; 2014 Apr; 27(3):206-13. PubMed ID: 23795569
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acid and non-acid reflux in Japanese patients with non-erosive reflux disease with persistent reflux symptoms, despite taking a double-dose of proton pump inhibitor: a study using combined pH-impedance monitoring.
    Iwakiri K; Kawami N; Sano H; Tanaka Y; Umezawa M; Kotoyori M; Hoshihara Y; Sakamoto C
    J Gastroenterol; 2009; 44(7):708-12. PubMed ID: 19434361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tailored therapy for the refractory GERD patients by combined multichannel intraluminal impedance-pH monitoring.
    Xiao Y; Liang M; Peng S; Zhang N; Chen M
    J Gastroenterol Hepatol; 2016 Feb; 31(2):350-4. PubMed ID: 26202002
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined esophageal multichannel intraluminal impedance and pH monitoring (MII -pH) in the diagnostics and treatment of gastroesophageal reflux disease and its complications.
    Masiak W; Wallner G; Wallner J; Pedowski T; Solecki M
    Pol Przegl Chir; 2011 Sep; 83(9):488-96. PubMed ID: 22166737
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action.
    Frazzoni M; Frazzoni L; De Bortoli N; Russo S; Tolone S; Arsiè E; Conigliaro R; Penagini R; Savarino E
    Aliment Pharmacol Ther; 2021 Jun; 53(11):1183-1189. PubMed ID: 33857331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy.
    Frazzoni M; Savarino E; Manno M; Melotti G; Mirante VG; Mussetto A; Bertani H; Manta R; Conigliaro R
    Aliment Pharmacol Ther; 2009 Sep; 30(5):508-15. PubMed ID: 19519732
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oropharyngeal pH Testing Does Not Predict Response to Proton Pump Inhibitor Therapy in Patients with Laryngeal Symptoms.
    Yadlapati R; Pandolfino JE; Lidder AK; Shabeeb N; Jaiyeola DM; Adkins C; Agrawal N; Cooper A; Price CP; Ciolino JD; Gawron AJ; Smith SS; Bove M; Tan BK
    Am J Gastroenterol; 2016 Nov; 111(11):1517-1524. PubMed ID: 27091320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.